Navigation Links
Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful complication of shingles, affects approximately 200,000 people a year in the US alone. The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness of SLC022 in controlling pain associated with PHN. Solace anticipates having results from the study in the second half of 2009.

SLC022 is an orally administered glial cell modulator that has shown efficacy in well-established preclinical pain models. Glial cells represent an important new target for the treatment of chronic pain based on their active role in neuronal pain signaling.

"The initiation of this study is another important milestone for Solace in our drive to discover and develop innovative treatments for pain," said Dr. Eliot Forster, Solace's Chief Executive Officer. "Our confidence in SLC022 is underpinned by a large body of prior preclinical and clinical data generated during the compound's previous development in a non-pain indication. We believe these data lower the development risk and enhance the opportunity for a favorable clinical profile."

Solace's advancement of SLC022 caps a year of significant progress. In 2008, Solace expanded its glial cell modulator program by identifying next-generation, novel leads with attractive drug properties. The company made equally rapid progress in optimizing inhibitors of the enzyme GTP cyclohydrolase 1 (GCH1), a key target within the BH4 synthesis pathway, and in identifying additional promising drug targets.

Solace Pharmaceuticals also established a two-year collaboration with Professor Keith Channon, MD FRCP, of the Department of Cardio
'/>"/>

SOURCE Solace Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
8. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
9. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
10. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015 MEDTEC China South 2015 came ... of MEDTEC China 2015, MEDTEC China South has been recognized ... out as a key event for the medical device manufacturing ... years of challenges, this year marks the successful return of the ... after the event first debuted there in 2005. ...
(Date:6/3/2015)...   Health Data Consortium (HDC) , a public-private partnership whose mission ... to improve health and healthcare, today announced Niall Brennan ... Office of Enterprise Data and Analytics at the Centers ... of this year,s Health Data Liberators Award ... ways to help improve the quality and value of ...
(Date:6/3/2015)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that Adapt ... overdose with intranasal naloxone, has commenced a rolling ... the United States Food and Drug Administration (FDA) ... drug intended to treat opioid overdose.  A rolling ...
Breaking Medicine Technology:MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 2CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 3CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 4Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... 18, 2011 Reportlinker.com announces that a ... its catalogue: China ... http://www.reportlinker.com/p0590608/China-Contract-Research-Organization-CRO-Industry-Report-2010-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc ... high R&D costs of new drugs worldwide, ...
... from Texas has invented a miraculous new medical laser ... inventions and scientific advancements in modern history. The miraculous ... organs to kill harmful germs and bacteria during surgical ... currently contribute to the estimated 100,000 annual deaths attributed ...
Cached Medicine Technology:China Contract Research Organization (CRO) Industry Report, 2010-2011 2China Contract Research Organization (CRO) Industry Report, 2010-2011 3China Contract Research Organization (CRO) Industry Report, 2010-2011 4China Contract Research Organization (CRO) Industry Report, 2010-2011 5New Life Saving Medical Invention Announced by Perry Felix 2
(Date:6/3/2015)... June 03, 2015 “ Harmony ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... that wants to improve some aspect of their life. , ... only for people with difficulties in their life. However, hypnotherapy ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On the heels ... $13 billion industry by 2020 ( click here to ... computer scientists believe Baltimore has the talent to ... in which genetic code and other biological data are collected ... disease. “Baltimore contains all the elements of a perfect ...
(Date:6/3/2015)... 03, 2015 Dr. Steven Reisman, a nationally ... Center ( http://www.newyorkcardiac.com ) located in NYC, announced today the ... his practice. In most cases, depending on the level of ... they call, they will be seen by a cardiologist that ... a cardiologist is to ensure that people who have an ...
(Date:6/3/2015)... WA (PRWEB) June 03, 2015 ... insurance exchange technology, has announced that CEO Jonathan Rickert ... Institute 2015 on June 4, 2015. The session ... digital technologies are disrupting traditional business models in health ... business value. , WHAT: Digital Transformation and the ...
Breaking Medicine News(10 mins):Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... which diet would work best for you, study suggests , WEDNESDAY, ... cut carbs or fats to lose weight? A DNA test using ... you, new research suggests. , Researchers from Stanford University used data ... women were assigned to one of four popular diets for a ...
... , ... ... ... ...
... ... ... ... ...
... Ill. -- A daily dose of vitamin D may just ... according to researchers at Loyola University Chicago Marcella Niehoff School ... months when days are short and more time is spent ... despite the nutrient,s widely reported health benefits," said Sue Penckofer, ...
... youth means trouble by mid-40s, despite activity levels, study finds , ... in their 20s and 30s are more apt to develop heart ... people who spent less time in front of the screen, a ... the worse news is that you can,t exercise the risk away. ...
... , ... ... ... ...
Cached Medicine News:Health News:A Cheek Swab to Choose Your Diet Plan? 2Health News:A Cheek Swab to Choose Your Diet Plan? 3Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 2Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 3Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 4Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 5Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 6Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 7Health News:Aspen Dental Announces Results of Its 'An Hour for Haiti' Employee Donation Program 2Health News:Aspen Dental Announces Results of Its 'An Hour for Haiti' Employee Donation Program 3Health News:Vitamin D lifts mood during cold weather months 2Health News:You Can't Exercise Away TV's Toll on the Heart 2Health News:You Can't Exercise Away TV's Toll on the Heart 3Health News:Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 2Health News:Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 3
... The VERSAPORT™ RT cannulas are all able ... systems packaged for use with the RT ... are all able to be used with ... with the RT system. The trocars include: ...
... trocar has a sharp linear blade and a ... VERSAPORT™ PLUS V2 trocar is available in 5 ... 5 mm-12 mm long sizes with a radiolucent ... has a sharp linear blade and a spring-loaded ...
... Auto Suture™ SPRING-GRIP™ single use nonconductive anchoring ... mm, 11 mm and 12 mm sizes ... and 5 mm, 5 mm-10 mm, 5 ... mm-15 mm sizes for use with the ...
... Access ...unlike any trocar system you've ever ... actually four systems in one designed ... adaptive to all of your needs., ... or dilating tip styles, OnePort™ can effectively ...
Medicine Products: